Inventor · disambiguated record
Richard S. Blumberg
Also filed as: BLUMBERG RICHARD · BLUMBERG RICHARD S
26 granted patents·36 pending applications·1,517 citations·filing 1995–2024
96Inventor score
Files withBRIGHAM & WOMENS HOSPITAL INC29BRIGHAM & WOMENS HOSPITAL9BLUMBERG RICHARD S6SYNTIMMUNE INC4STROBER WARREN2
Top patents by PatentIndex Score
62 records- 0198US7132255B2Identification of compounds that bind biliary glycoprotein and affect cytotoxic T lymphocyte activityBRIGHAM & WOMENS HOSPITAL·Filed 2005·Granted Nov 7, 2006·122 cites·2 claims
- 0297US6485726B1Receptor specific transepithelial transport of therapeuticsBRIGHAM & WOMENS HOSPITAL·Filed 1998·Granted Nov 26, 2002·371 cites·10 claims
- 0397US6030613AReceptor specific transepithelial transport of therapeuticsBRIGHAM & WOMENS HOSPITAL·Filed 1997·Granted Feb 29, 2000·436 cites·34 claims
- 0495US7067129B2Receptor specific transepithelial transport in therapeuticsUNIV BRANDEIS·Filed 2002·Granted Jun 27, 2006·56 cites·28 claims
- 0594US7060274B2Receptor specific transepithelial transport of therapeuticsUNIV BRANDEIS·Filed 2002·Granted Jun 13, 2006·53 cites·12 claims
- 0694US6086875AReceptor specific transepithelial transport of immunogensBRIGHAM & WOMENS HOSPITAL·Filed 1995·Granted Jul 11, 2000·403 cites·12 claims
- 0791US9556271B2Anti-CEACAM1 recombinant antibodies for cancer therapyBRIGHAM & WOMENS HOSPITAL INC·Filed 2012·Granted Jan 31, 2017·23 cites·9 claims
- 0889US6852320B2T cell inhibitory receptor compositions and uses thereofBRIGHAM & WOMENS HOSPITAL·Filed 2001·Granted Feb 8, 2005·27 cites·14 claims
- 0984US10588935B2FC receptor (FcRn) binding peptides and uses thereofBRIGHAM & WOMENS HOSPITAL INC·Filed 2019·Granted Mar 17, 2020·2 cites·14 claims
- 1083US10046023B2FC receptor (FcRn) binding peptides and uses thereofBRIGHAM & WOMENS HOSPITAL INC·Filed 2016·Granted Aug 14, 2018·2 cites·11 claims
- 1182US9527890B2FC receptor (FcRn) binding peptides and uses thereofTHE BRIGHAM AND WOMENS'S HOSPITAL INC·Filed 2014·Granted Dec 27, 2016·5 cites·9 claims
- 1282US7547436B2Receptor specific transepithelial transport of therapeuticsBRIGHAM & WOMENS HOSPITAL·Filed 2006·Granted Jun 16, 2009·1 cites·17 claims
- 1379US10626175B2Humanized affinity matured anti-FcRn antibodiesSYNTIMMUNE INC·Filed 2017·Granted Apr 21, 2020·2 cites·2 claims
- 1476US10822417B2Humanized affinity matured anti-FcRn antibodiesSYNTIMMUNE INC·Filed 2017·Granted Nov 3, 2020·2 cites·9 claims
- 1576US2025263487A1Methods to manipulate alpha-fetoprotein (afp)BRIGHAM & WOMENS HOSPITAL INC·Filed 2024·Application pending·0 cites
- 1674US8821866B2Methods of treating and preventing colitis involving IL-13 and NK-T cellsSTROBER WARREN·Filed 2012·Granted Sep 2, 2014·2 cites·3 claims
- 1773US8173123B2Methods of treating colitis involving IL-13 and NK-T cellsSTROBER WARREN·Filed 2010·Granted May 8, 2012·2 cites·4 claims
- 1873US2021347887A1Compositions and methods for modulating an immune responseBRIGHAM & WOMENS HOSPITAL INC·Filed 2021·Application pending·0 cites
- 1971US7666411B2Methods of treating and preventing colitis involving IL-13 and NK-T cellsUS HEALTH·Filed 2002·Granted Feb 23, 2010·4 cites·5 claims
- 2070US2025074980A1Humanized and Affinity-Matured Anti-CEACAM1 AntibodiesTHE BRIGHAM AND WOMEN’S HOSPITAL INC·Filed 2024·Application pending·0 cites
- 2169US8232067B2Disrupting FCRN-albumin interactionsBLUMBERG RICHARD S·Filed 2010·Granted Jul 31, 2012·3 cites·19 claims
- 2267US2019183964A1FC RECEPTOR (FcRn) BINDING PEPTIDES AND USES THEREOFBRIGHAM & WOMENS HOSPITAL INC·Filed 2018·Application pending·0 cites
- 2366US12110333B2Methods to manipulate alpha-fetoprotein (AFP)BRIGHAM & WOMENS HOSPITAL INC·Filed 2019·Granted Oct 8, 2024·0 cites·19 claims
- 2463US10035858B2Compositions and methods for modulating an immune responseBRIGHAM & WOMENS HOSPITAL INC·Filed 2014·Granted Jul 31, 2018·0 cites·2 claims
- 2563US2020040076A1Compositions and methods for modulating an immune responseBRIGHAM & WOMENS HOSPITAL INC·Filed 2019·Application pending·0 cites
- 2663US2020241001A1Compositions and methods for treating subjects with immune-mediated diseasesBRIGHAM & WOMENS HOSPITAL INC·Filed 2019·Application pending·0 cites
- 2761US2020024343A1Compositions and methods for modulating an immune responseBRIGHAM & WOMENS HOSPITAL INC·Filed 2019·Application pending·0 cites
- 2860US12173066B2Humanized and affinity-matured anti-CEACAM1 antibodiesBRIGHAM & WOMENS HOSPITAL INC·Filed 2019·Granted Dec 24, 2024·0 cites·23 claims
- 2960US2019169290A1Compositions and methods for modulating an immune responseBRIGHAM & WOMENS HOSPITAL INC·Filed 2018·Application pending·0 cites
- 3059US10329315B2Glycosphingolipids and methods of use thereofBRIGHAM & WOMENS HOSPITAL INC·Filed 2013·Granted Jun 25, 2019·1 cites·18 claims
- 3159US2025388666A1Humanized and affinity-matured anti-ceacam1 antibodies and methods of useTHE BRIGHAM AND WOMEN’S HOSPITAL INC·Filed 2023·Application pending·0 cites
- 3259US2020207854A1HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIESSYNTIMMUNE INC·Filed 2020·Application pending·0 cites
- 3359US2020181262A1HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIESSYNTIMMUNE INC·Filed 2020·Application pending·0 cites
- 3458US8110189B2T cell inhibitory receptor compositions and uses thereofBLUMBERG RICHARD S·Filed 2006·Granted Feb 7, 2012·0 cites·3 claims
- 3558US2020095284A1Modulation of the immune responseBRIGHAM & WOMENS HOSPITAL INC·Filed 2019·Application pending·0 cites
- 3657US10513540B2Modulation of the immune responseBRIGHAM & WOMENS HOSPITAL INC·Filed 2013·Granted Dec 24, 2019·0 cites·8 claims
- 3756US2025154251A1Companion diagnostic for human ceacam1 directed therapeutic agentsBRIGHAM & WOMENS HOSPITAL INC·Filed 2023·Application pending·0 cites
- 3855US2020031928A1Methods to manipulate alpha-fetoprotein (afp)BRIGHAM & WOMENS HOSPITAL INC·Filed 2019·Application pending·0 cites
- 3955US2005090426A1Methods of inhibiting inflammationFiled 2004·Application pending·0 cites
- 4055US2017000899A1Receptor-targeted nanoparticles for enhanced transcytosis mediated drug deliveryBRIGHAM & WOMENS HOSPITAL INC·Filed 2014·Application pending·0 cites
- 4154US2012141470A1T cell inhibitory receptor compositions and uses thereofBLUMBERG RICHARD S·Filed 2011·Application pending·0 cites
- 4252US2004063912A1Central airway administration for systemic delivery of therapeuticsBRIGHAM & WOMENS HOSPITAL·Filed 2003·Application pending·0 cites
- 4350US2004047858A1Therapeutic anti-BGP(C-CAM1) antibodies and uses thereofFiled 2002·Application pending·0 cites
- 4450US2003235536A1Central airway administration for systemic delivery of therapeuticsBRIGHAM & WOMENS HOSPITAL·Filed 2003·Application pending·0 cites
- 4549US2006140907A1Central airway administration for systemic delivery of therapeuticsBLUMBERG RICHARD S·Filed 2006·Application pending·0 cites
- 4648US2005234073A1Methods of inhibiting inflammationBLUMBERG RICHARD S·Filed 2005·Application pending·0 cites
- 4748US2015273056A1Enhancement of the immune responseBRIGHAM & WOMENS HOSPITAL·Filed 2013·Application pending·0 cites
- 4848US2019201524A1Enhancement of the immune responseBRIGHAM & WOMENS HOSPITAL INC·Filed 2018·Application pending·0 cites
- 4945US9689044B2Assays and methods to sequence microbes directly from immune complexesBLUMBERG RICHARD S·Filed 2012·Granted Jun 27, 2017·0 cites·19 claims
- 5045US2018021455A1Receptor-targeted nanoparticles for enhanced transcytosis mediated drug deliveryBRIGHAM & WOMENS HOSPITAL INC·Filed 2017·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Richard S. Blumberg files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →